Zoetis (ZTS) Stock Forecast & Price Target

Zoetis has demonstrated significant growth in its pet-owner engagement, with enrollment in the Zoetis Petcare Rewards program increasing to 2.5 million participants from 708,000 in 2018, supported by over $120 million invested in 2023 for direct-to-consumer marketing initiatives in the U.S. The company's product Simparica delivered strong performance in Q3, generating $356 million in revenue, reflecting a year-over-year growth of 7%. Additionally, key dermatology products, including Apoquel and Cytopoint, contributed $469 million in global revenue, marking a 3% year-over-year increase, underscoring Zoetis's robust position in both the companion and production animal health markets.

The fundamental outlook on Zoetis's stock is negative due to a lowered revenue guidance for 2025, revised down to $9.400 billion to $9.475 billion, reflecting a decline in anticipated organic operational growth from previous estimates. Furthermore, the company's operational challenges are highlighted by an 11% year-over-year decline in its OA pain business, driven by safety concerns related to its product Librela. Additionally, disappointing sales in the core U.S. companion animal health segment, which fell short of expectations amid increased competition and a decline in vet clinic visits, further exacerbate the company's financial prospects.